Standard-Dose Trifluridine/Tipiracil as Safe Treatment Alternative in Metastatic Colorectal Cancer Patients With DPD Deficiency

Clin Colorectal Cancer. 2021 Dec;20(4):359-363. doi: 10.1016/j.clcc.2021.09.004. Epub 2021 Sep 15.

Authors

Jeroen F Schouten¹, Jeroen Willems², Stefan J W J Sanders¹, Geert-Jan Creemers², Maarten J Deenen³

Affiliations

¹ Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.
² Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.
³ Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands; Department of Clinical Pharmacology and Toxicology, Leiden University Medical Centre, Leiden, the Netherlands. Electronic address: Maarten.deenen@catharinaziekenhuis.nl.

PMID: 34645590
DOI: 10.1016/j.clcc.2021.09.004

No abstract available

Keywords: 5-fluorouracil; Capecitabine; Clinical pharmacology; Dihydropyrimidine dehydrogenase; TAS-102; Toxicity.

Publication types

Case Reports

MeSH terms

Colonic Neoplasms*
Dihydropyrimidine Dehydrogenase Deficiency*
Humans
Pyrrolidines
Rectal Neoplasms*
Thymine
Trifluridine / adverse effects

Substances

Pyrrolidines
tipiracil
Thymine
Trifluridine